Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
Globe Newswire•26/08/2026•08:30 ET
0
Whiz Insights
Get started
Create a free account to read the full story.
Create a free account to read the full story.